Chagas Disease - Pipeline Review, H1 2017

Publisher Name :
Date: 16-May-2017
No. of pages: 83
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 4 molecules, respectively.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Chagas Disease - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chagas Disease (American Trypanosomiasis) - Overview
Chagas Disease (American Trypanosomiasis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Bayer AG
Daiichi Sankyo Company Ltd
Eisai Co Ltd
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
KaloBios Pharmaceuticals Inc
Kancera AB
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Chagas Disease (American Trypanosomiasis) - Drug Profiles
benznidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benznidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLBS-1246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLBS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexinidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravuconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNF-6702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0441411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAO-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEU-321 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VNI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas Disease (American Trypanosomiasis) - Dormant Projects
Chagas Disease (American Trypanosomiasis) - Discontinued Products
Chagas Disease (American Trypanosomiasis) - Product Development Milestones
Featured News & Press Releases
Apr 06, 2017: Benznidazole on Track in Progress to IND and NDA Submissions
Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole
Dec 12, 2016: KaloBios Completes Meeting with FDA for Benznidazole
Nov 15, 2016: Bayer to Fight Chagas Disease in Children
Aug 08, 2016: A single compound could treat three parasitic diseases
Apr 11, 2016: KaloBios Announces New Product Pricing Model
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world
Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Kancera AB, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2017
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2017
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global Cephalosporin Market Research Report 2017
    Published: 19-Sep-2017        Price: US 2900 Onwards        Pages: 155
    In the last several years, global market of Cephalosporin developed rapidly, with an average growth rate of 5.5%. In 2016, global revenue of Cephalosporin is nearly 3700 M USD; the actual production is about 18600 MT. This report studies Cephalosporin in Global market, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Union Chempharma NCPC Qilu Antibiotics Lupin Pharmaceutical......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2017
    Published: 19-Sep-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Drugs for Herpes Labialis (Oral Herpes) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Drugs for Herpes Labialis (Oral Herpes) in these regions, from 2012 to 2022 (forecast), covering - North Ame......
  • United States Drugs for Clostridium Difficile Infections Market Report 2017
    Published: 19-Sep-2017        Price: US 3800 Onwards        Pages: 115
    In this report, the United States Drugs for Clostridium Difficile Infections market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), marke......
  • Global Drugs for Clostridium Difficile Infections Sales Market Report 2017
    Published: 15-Sep-2017        Price: US 4000 Onwards        Pages: 124
    In this report, the global Drugs for Clostridium Difficile Infections market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Drugs for Clostridium Difficile Infections for these regions, from 2012 to 2022 (forecast), covering - United Sta......
  • Global Polymixin Market Research Report 2017
    Published: 14-Sep-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Polymixin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Polymixin in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - ......
  • Global Cephalosporin Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 14-Sep-2017        Price: US 3480 Onwards        Pages: 118
    "Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium""." Scope of the Report: This report focuses on the Cephalosporin in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions,......
  • Global Cefazolin Sodium Market Research Report 2017
    Published: 13-Sep-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Cefazolin Sodium market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cefazolin Sodium in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - J......
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 51
    Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever - Pipeline Review, H2 2017, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or house......
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 264
    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Sign......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs